Thiotropium in bronchial asthma


Cite item

Full Text

Abstract

About the authors

S N Avdeev

S N Avdeev

References

  1. Global Initiative for Asthma (GINA) Executive Committee, Global Strategy for Asthma Management and Prevention. GINA 2006. www.ginasthma.com
  2. Vincken W. Bronchodilator treatment of stable COPD: long-acting anticholinergics. Eur Respir. Rev. 2005; 14: 23-31.
  3. Panning С. A., DeBisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003; 23: 183-189.
  4. Rodrigo G. J., Rodrigo C. The role of anticholinergics in acute asthma treatment. An evidence-based evaluation. Chest 2002; 121: 1977-1987.
  5. Авдеев С. Н. Роль комбинированного использования b2-агонистов и антихолинергических препаратов при бронхиальной астме. Пульмонология 2003; 2: 117-123.
  6. Авдеев С. Н. Роль антихолинергических препаратов при обструктивных заболеваниях легких. Consilium Medicum 2002; 4: 478-485.
  7. Kanazawa H. Anticholinergic agents in asthma: chronic bronchodilator therapy, relief of acute severe asthma, reduction of chronic viral inflammation and prevention of airway remodeling. Curr. Opin. Pulm. Med. 2006; 12: 60-67.
  8. Barnes P. J. Theoretical aspects of anticholinergic treatment. In: Gross N., ed. Anticholinergic therapy in obstructive lung disease. London: Franklin Scientific Publication; 1993. 88-104.
  9. Gross N. J., Skorodin M. S. Anticholinergic, antimuscarinic bronchodilators. Am. Rev. Respir. Dis. 1984; 129: 856-870.
  10. Gross N. J., Barnes P. J. A short tour around the muscarinic receptor. Am. Rev. Respir. Dis. 1988; 138: 765-767.
  11. Molfino N. A., Slutsky A. S., Julia-Serda G. et al. Assessment of airway tone in asthma. Am. Rev. Respir. Dis. 1993; 148: 1238-1243.
  12. Barnes P. J. Modulation of neurotransmission in airways. Physiol. Rev. 1992; 72: 699-729.
  13. Ayala L. E., Ahmed T. Is there loss of protective muscarinic receptor mechanism in asthma? Chest 1989; 96: 1285-1291.
  14. Kanazawa H., Kawaguchi T., Shoji S. et al. Synergistic effect of nitric oxide and vasoactive intestinal peptide on bronchoprotection against histamine in anesthetized guinea pigs. Am. J. Respir. Crit. Care. Mede. 1997; 155: 747-750.
  15. Fryer A. D., Jacoby D. B. Parainfluenza virus infection damages inhibitory M2-muscarinic receptors on pulmonary parasympathetic nerves in the guinea pig. Br. J. Pharmacol. 1991; 102: 267-271.
  16. Fryer A. D., Jacoby D. B. Effect of inflammatory cell mediators on M2-muscarinic receptors in the lungs. Life Sci. 1993; 52: 529-536.
  17. Chhabra S., Pandey K. K. Comparison of acute bronchodilator effects of inhaled ipratropium bromide and salbutamol in bronchial asthma. J. Asthma 2002; 39: 375-381.
  18. Casaburi R., Briggs D. D., Donohue J. F. et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000; 118: 1294-1302.
  19. Disse B., Speck G. A., Rominger K. L. et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999; 64: 457-464.
  20. Barnes P. J., Belvisi M. G., Mak J. C. W. et al. Tiotropium bromide (Ba 679 BR), a novel long-acting muscarinic antagonist for the treatment of obstructive airways diseases. Life Sci. 1995; 56: 853-859.
  21. O'Connor B. J., Towse L. J., Barnes P. J. Prolonged effect of tiotropium bromide on niethacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 1996; 154: 876-880.
  22. Ohta S., Minoguchi K., Oda N. et al. Effects of tiotropium bromide on allergen induced airway inflammation and remodeling in murine model of asthma. Yn: American Thoracic Society 2008 International conference; 2008. Abstr. A65.
  23. Sayal P., Adhikari T., Vijayan V. K. The effects of inhaled tiotropium bromide on lung inflammation in bronchial asthma. Chest 2007; 132 (suppl.): 509S.
  24. Fardon T., Haggart K., Lee D. K. C., Lipworth B. J. A proof of concept study to evaluate stepping down the dose of fluticasone in combination with salmeterol and tiotropium in severe persistent asthma. Respir. Med. 2007; 101: 1218-1228.
  25. Terzano C., Petroianni A., Ricci A. et al. Early protective effect of tiotropium bromide in patients with hyperresponsiveness. Eur. Rev. Med. Pharm. Sci. 2004; 8: 259-264.
  26. Bousquet J., Jeffery P. K., Busse W. W. et al. Asthma: from bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. 2000; 161: 1720-1745.
  27. Johnson P. R., Black J. L., Carlin S. et al. The production of extracellular matrix proteins by human passively sensitized airway smooth-muscle cells in culture: the effect of beclomethasone. Am. J. Respir. Crit. Care Med. 2000; 162: 2145-2151.
  28. Gosens R., Nelemans S. A., Grootte Bromhaar M. M. et al. Muscarinic М3-receptors mediate cholinergic synergism of mitogenesis in airway smooth muscle. Am. J. Respir. Cell. Mol. Biol. 2003; 28: 257-262.
  29. Krymskaya V. P., Orsini M. J., Eszterhas A. J. et al. Mechanisms of proliferation synergy by receptor tyrosine kinase and G protein-coupled receptor activation in human airway smooth muscle. Am. J. Respir. Cell. Mol. Biol. 2000; 23: 546-554.
  30. Asai K., Kanazawa H., Kamoi H. et al. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin. Exp. Allergy 2003; 33: 595-599.
  31. Amishima M., Munakata M., Nasuhara Y. et al. Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am. J. Respir. Crit. Care Med. 1998; 157: 1907-1912.
  32. Gosens R., Bos I. S., Zaagsma J., Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am. J. Respir. Crit. Care Med. 2005; 171: 1096-1102.
  33. Gosens R., Zaagsma J., Meurs H., Halayko A. J. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir. Res. 2006; 7: 73.
  34. Bos I. S., Gosens R., Zuidhof A. B. et al. Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison. Eur. Respir. J. 2007; 30: 653-661.
  35. Wenzel S. Severe asthma in adults. Am. J. Respir. Crit. Care Med. 2005; 172: 149-160.
  36. Barnes P. J., Woolcock A. J. Difficult asthma. Eur. Respir. J. 1998; 12: 1209-1218.
  37. Chung K. F., Godard P., Adelroth E. et al. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies;
  38. ERS Task Force on Difficult/Therapy-Resistant Asthma; European Respiratory Society. Eur. Respir. J. 1999; 13: 1198-1208. 38. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions: American Thoracic Society. Am. J. Respir. Crit. Care Med. 2000; 162: 2341-2351.
  39. Heaney L. G., Robinson D. S. Severe asthma treatment: need for characterising patients. Lancet 2005; 365: 974-976.
  40. Shrewsbury S., Руке S., Britton M. Meta-analysis of increased dose of inhaled steroid or addiction of salmeterol in symptomatic asthma (MIASMA). Br. Med. J. 2000; 320: 1368-1373.
  41. Pauwels R. A., Lofdahl C. G., Postma D. S. et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N. Engl. J. Med. 1997; 337: 1405-1411.
  42. Suzuki N. Long-term effect of additional tiotropium bromide on pulmonary function in patients with severe chronic asthma. In: American Thoracic Society 2008 International conference; 2008. abstr. A58.
  43. ten Brinke A., Zwinderman A. H., Sterk P. J. et al. Factors associated with persistent airflow limitation in severe asthma. Am. J. Respir. Crit. Care Med. 2001; 164: 744-748.
  44. Feschenko Y., Yashyna L., Gorovenko N. et al. Influence of combined antiasthmatic basic therapy on hyperinflation in patients with severe bronchial asthma. Eur. Respir. J. 2007; 30 (suppl.): 553s-554s.
  45. O'Donnell D. E., Fluge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23: 832-840.
  46. Van Schayck C. P., Folgering H., Harbers H. et al. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Thorax. 1991; 46: 355-359.
  47. Westby M., Benson M., Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst. Rev. 2004; 3: CD003269.
  48. Gross N. J. Anticholinergic agents in asthma and COPD. Eur. J. Pharmacol. 2006; 533: 36-39.
  49. Iwamoto H., Yokoyama A., Shiota N. et al. Tiotropium bromide is effective for severe asthma with noneosinophilic phenotype. Eur. Respir. J. 2008; 31:.1379-1380.
  50. Haldar P., Pavord I. D. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J. Allergy Clin. Immunol. 2007; 119: 1043-1052.
  51. Gibson P. G., Simpson J. L., Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119: 1329-1336.
  52. Brims F., Fehrenbach C., Chauhan A. Tiotropium in severe asthma: an open label review of clinical efficacy. Eur. Respir. J. 2007; 30 (suppl.): 616s.
  53. Fabbri L. M., Romagnoli M., Corbetta L. et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 167: 418-424.
  54. Soriano J. B., Davis K. J., Coleman B. et al. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest 2003; 124: 474-481.
  55. Rabe K. F., Hurd S., Anzueto A. et al. Global strategy for the diagnosis, management, and prevention of COPD: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532-555.
  56. Magnussen H., Bugnas B., van Noord J. et al. Improvements with tiotropium in COPD patients with concomitant asthma. Respir. Med. 2008; 102: 50-56.
  57. Magnussen H., Bugnas B., van Noord J. et al. COPD and Concomitant Asthma: Efficacy of Tiotropium in Different Age, PEFR Variability and Bronchoclilator Responsiveness Groupings. In: American Thoracic Society 2008 International conference; 2008. abstr. A649.
  58. Iwanaga T., Naito E., Ichihashi H. et al. The effect of tiotropium in COPD complicated with asthma. Eur. Respir. J. 2007; 30 (suppl.): 610s.
  59. Hisada T., Ishizuka T., Aoki H. et al. Additive benefits of tiotropium in asthmatics and in patients with asthma complicated chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 30 (suppl.): 546s.
  60. Ullach M. I., Newman G. B., Saunders K. B. Influence of age on response to ipratropium and salbutamol in asthma. Thorax 1981; 36: 523-529.
  61. Catterall J. R., Rhind G. B., Whyte K. F. et al. Is nocturnal asthma caused by changes in airway cholinergic activity? Thorax 1988; 43: 720-724.
  62. Israel E., Drazen J. M., Liggett S. B. et al. The effect of polymorphisms of the beta (2)-adrenergic receptor on their response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. 2000; 162: 75-80.
  63. Taylor D. R., Drazen J. M., Herbison G. P. et al. Asthma exacerbations during long term beta agonist use: influence of beta (2) adrenoceptor polymorphism. Thorax 2000; 55: 762-767.
  64. Israel E., Chinchilli V. M., Ford J. G. et al. Use of regulatory scheduled albuterol treatment in asthma: genotype-statified, randomized, placebo-controlled cross-over trial. Lancet 2004; (23): 1505-1512.
  65. Efficacy and safety of tiotropium and salmeterol in moderate persistent asthma patients homozygous for B16-Arg/Arg. ClinicalTrials.gov Identifier: NCT00350207.
  66. Corrigan C. J., Brown P. H., Barnes N. C. et al. Glucocorticoid resistance in chronic asthma: peripheral blood T lymphocyte activation and comparison of the T lymphocyte inhibitory effects of glucocorticoids and cyclosporin A. Am. Rev. Respir. Dis. 1991; 144: 1016-1025.
  67. Yamada K., Elliott W. M., Hayashi S. et al. Latent adenoviral infection modifies the steroid response in allergic lung inflammation. J. Allergy Clin. Immunol. 2000; 106: 844-851.
  68. Kanazawa H., Yoshikawa J. Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis С virus infection: A 6-year follow-up study. Am. J. Med. 2004; 116: 749-752.
  69. Kanazawa H., Yoshikawa J. Alteration of T lymphocyte subsets in asthmatic airways with active hepatitis С virus infection. Respiration 2006; 73: 318-323.
  70. Kanazawa H., Hirata K., Yoshikawa J. Increased responses to inhaled oxitropum bromide in asthmatic patients with active hepatitis С virus infection. Chest 2004; 125: 1368-1371.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies